Watching local relapse after high-grade osteosarcoma treatment
Part of Cancer clinical trials.
This study is watching people whose high-grade osteosarcoma came back in the same bone area (local relapse) after treatment. It helps doctors understand how local relapse happens, so they can improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a high-grade osteosarcoma (a type of bone cancer) that came back in the same area (local recurrence) after initial treatment.
- The local recurrence was the first sign that the cancer returned (not spread to other parts of the body first).
- If you had lung spots when first diagnosed, you can still join.
- You are willing to come to follow-up visits and give permission to use your medical data.
- There is no age limit—anyone can take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a registry that collects health and medical history from people with osteosarcoma and related bone cancers. It may help researchers learn how these cancers behave and support better future studies.
This Phase 1/2 study tests how safe and how well vactosertib works for adolescents and adults with osteosarcoma that has returned, stopped responding, or is getting worse despite prior treatment. You may be able to join if you meet age, cancer, recovery-from-prior-therapy, and health-test requirements.
This trial focuses on improving how osteosarcoma care is coordinated and delivered, using collaboration between clinicians. It may help by helping teams make more consistent treatment decisions for people newly diagnosed.
This Phase 2 study tests whether regorafenib, given after your main treatments, can help keep high-grade bone sarcoma from coming back or progressing. It checks safety and whether this “maintenance” approach works better than best supportive care alone.
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
This early-phase study tests whether adding losartan to sunitinib can help control osteosarcoma that has returned or keeps growing after at least one prior treatment. It may help by targeting the cancer’s growth signals and blood supply, but the goal at this stage is mainly to check safety and find workable dosing.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.